On the upside, Schabel says, the emergence of the vaccine shows how investments in breast cancer research are paying off. “The research community is coming at this from many directions, and that is a very positive thing,” she says. “This is novel, and thinking out of the box is always good.” It may take a decade for Tuohy’s vaccine to hit the market—so Schabel’s advice is to watch and wait: “This may not be ready for you, but it might be ready for your daughters.”